Literature DB >> 31097997

Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation.

Lijie Peng1, Zhensheng Zhang1, Chong Lei1, Shan Li1, Zhang Zhang1, Xiaomei Ren1, Yu Chang1, Yan Zhang2, Yong Xu2, Ke Ding1.   

Abstract

A series of (E)-3-(4-((2,4-bis(trifluoromethyl)benzyl)oxy)-3-methoxyphenyl)-2-cyanoacrylamide derivatives were designed and synthesized as new estrogen-related receptor α (ERRα) degraders based on the proteolysis targeting chimera (PROTAC) concept. One of the representative compounds 6c is capable of specifically degrading ERRα protein by >80% at a relatively low concentration of 30 nM, becoming one of the most potent and selective ERRα degraders to date. Compound 6c could be utilized as a new powerful research tool for further biological investigation of ERRα.

Entities:  

Year:  2019        PMID: 31097997      PMCID: PMC6512006          DOI: 10.1021/acsmedchemlett.9b00025

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  42 in total

Review 1.  Orphan nuclear receptors: from gene to function.

Authors:  V Giguère
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

Review 2.  Proteolysis: from the lysosome to ubiquitin and the proteasome.

Authors:  Aaron Ciechanover
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

Review 3.  Metabolic regulation by the nuclear receptor corepressor RIP140.

Authors:  Mark Christian; Roger White; Malcolm G Parker
Journal:  Trends Endocrinol Metab       Date:  2006-07-11       Impact factor: 12.015

4.  What is the right dose? The elusive optimal biologic dose in phase I clinical trials.

Authors:  Alex A Adjei
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

5.  Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha.

Authors:  Brett B Busch; William C Stevens; Richard Martin; Peter Ordentlich; Sihong Zhou; Douglas W Sapp; Robert A Horlick; Raju Mohan
Journal:  J Med Chem       Date:  2004-11-04       Impact factor: 7.446

Review 6.  Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator.

Authors:  Pere Puigserver; Bruce M Spiegelman
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

7.  Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.

Authors:  L Meng; R Mohan; B H Kwok; M Elofsson; N Sin; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

8.  Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor.

Authors:  Takashi Suzuki; Yasuhiro Miki; Takuya Moriya; Norihiro Shimada; Takanori Ishida; Hisashi Hirakawa; Noriaki Ohuchi; Hironobu Sasano
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

Review 9.  To ERR in the estrogen pathway.

Authors:  Vincent Giguère
Journal:  Trends Endocrinol Metab       Date:  2002-07       Impact factor: 12.015

10.  Reduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptor alpha.

Authors:  Jiangming Luo; Robert Sladek; Julie Carrier; Jo-Ann Bader; Denis Richard; Vincent Giguère
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

View more
  13 in total

Review 1.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 2.  Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.

Authors:  Zhenyi Hu; Craig M Crews
Journal:  Chembiochem       Date:  2021-09-23       Impact factor: 3.461

3.  Zearalenone promotes follicle development through activating the SIRT1/PGC-1α signaling pathway in the ovaries of weaned gilts.

Authors:  Boyang Wan; Libo Huang; Changwei Jing; Yang Li; Ning Jiao; Ming Liang; Shuzhen Jiang; Weiren Yang
Journal:  J Anim Sci       Date:  2022-04-01       Impact factor: 3.338

4.  Covalent PROTACs: the best of both worlds?

Authors:  Neil P Grimster
Journal:  RSC Med Chem       Date:  2021-07-15

5.  Discovery of a Novel Class of ERRα Agonists.

Authors:  Tsuyoshi Shinozuka; Shuichiro Ito; Takako Kimura; Masanori Izumi; Kenji Wakabayashi
Journal:  ACS Med Chem Lett       Date:  2021-04-21       Impact factor: 4.345

Review 6.  Nuclear receptors in the kidney during health and disease.

Authors:  Andrew E Libby; Bryce Jones; Isabel Lopez-Santiago; Emma Rowland; Moshe Levi
Journal:  Mol Aspects Med       Date:  2020-11-30

Review 7.  Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers.

Authors:  Li Liu; Lihong Shi; Zhaodi Wang; Jun Zeng; Yue Wang; Hongtao Xiao; Yongxia Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-18       Impact factor: 5.555

Review 8.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

9.  Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.

Authors:  Guoshun Luo; Zhenbang Li; Xin Lin; Xinyu Li; Yu Chen; Kun Xi; Maoxu Xiao; Hanlin Wei; Lizhe Zhu; Hua Xiang
Journal:  Acta Pharm Sin B       Date:  2020-11-06       Impact factor: 11.413

Review 10.  Light-Controllable PROTACs for Temporospatial Control of Protein Degradation.

Authors:  Jing Liu; Yunhua Peng; Wenyi Wei
Journal:  Front Cell Dev Biol       Date:  2021-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.